Online publication ahead of print, AJMHS Vol 63, 2023

Zinc Superoxide Dismutase and Amyotrophic Lateral Sclerosis: Deciphering the Role and Implications for Therapeutic Interventions

Eugerta Avdulaj[1*], Ardijan Cobaj[2], Blerta Qinami[1]

[1] University of Medicine, Tirana, Albania
[2] Peace Corps Albania and Montenegro

Abstract

Amyotrophic lateral sclerosis (ALS) stands as a complex and devastating neurodegenerative disorder characterized by the progressive degeneration of motor neurons, ultimately leading to paralysis and respiratory failure. Despite extensive research, the intricate molecular underpinnings of ALS remain elusive, hampering therapeutic advancements. This narrative review delves into the intriguing link between copper-zinc superoxide dismutase (CuZnSOD) and ALS pathogenesis. CuZnSOD, a metalloenzyme essential for maintaining cellular redox balance by neutralizing superoxide radicals, becomes a paradoxical player in select ALS cases.

Early identification of SOD1 mutations paved the way for understanding familial ALS, shedding light on the intricate interplay between genetic factors and neurodegeneration. Mutant SOD1 proteins have been implicated in protein misfolding and aggregation within motor neurons, creating a toxic environment that triggers cellular stress and inflammation. Notably, the relationship between CuZnSOD and metal ions, particularly copper and zinc, adds complexity to ALS pathology. Proper folding and function of CuZnSOD hinge on these metal ions, and disruptions in metal homeostasis may induce SOD1 misfolding, accentuating protein aggregation and oxidative stress. Perturbations in

Address for correspondence: Eugerta Avdulaj*, University of Medicine, Tirana, Albania. Email: eugerta.avdulaj@yahoo.com

copper and zinc levels have been observed in ALS motor neurons, hinting at a potential role in disease progression.

Through a synthesis of genetic and mechanistic insights, this review underscores the multifaceted connections between CuZnSOD, mutant SOD1, oxidative stress, and ALS pathogenesis. We navigate the nuanced landscape of ALS research, emphasizing the interdisciplinary collaboration required to unravel its complexities. By probing into the dynamic relationship between CuZnSOD, metal ions, and ALS, we aim to illuminate the molecular intricacies driving motor neuron degeneration and stimulate innovative therapeutic avenues. This narrative review serves as a compass, guiding researchers toward a comprehensive understanding of ALS and its complex interplay with CuZnSOD- mediated mechanisms.

Keywords: Zinc superoxide dismutase, ZnSOD, Amyotrophic lateral sclerosis, Therapeutic interventions, Genetic predisposition.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder that primarily targets motor neurons, leading to muscle weakness, paralysis, and ultimately, respiratory failure. Despite decades of research, the intricate etiology of ALS remains enigmatic, hampering the development of effective therapeutic interventions. One intriguing avenue of investigation involves the study of metalloenzymes known as superoxide dismutase (SODs), with a particular focus on the CuZnSOD isoform. Emerging evidence suggests a pivotal role of CuZnSOD in ALS pathogenesis, underlining the intricate interplay between metal homeostasis, oxidative stress and neurodegeneration (1, 2).

CuZnSOD, also known as SOD1, is a ubiquitous enzyme that plays a central role in the cellular antioxidant defense mechanism. By catalyzing the dismutation of superoxide radicals to oxygen and hydrogen peroxide, CuZnSOD prevents the accumulation of reactive oxygen species (ROS) that can wreak havoc on cellular components. However, the very enzyme designed to protect cells from oxidative damage paradoxically becomes a culprit in certain forms of ALS.

Notably, mutations in the SOD1 gene were among the first genetic alterations linked to familial ALS cases. These mutations were initially identified as the cause of approximately 20% of familial ALS cases, unraveling the intricate connection between genetic predisposition and neurodegeneration (1). Moreover, various studies have underscored the implications of SOD1 misfolding and aggregation in the pathogenesis of ALS (2,3). The aggregation of mutant SOD1 proteins within motor neurons creates a toxic microenvironment, promoting cellular stress and subsequent neuroinflammation.

Furthermore, the close relationship between SOD1 and metal ions, particularly copper and zinc, adds another layer of complexity to ALS pathology. Copper and zinc binding are critical for CuZnSOD's proper folding and enzymatic activity. Any disturbances in metal homeostasis can potentially result in the misfolding of SOD1, thus fueling aberrant protein aggregation and oxidative stress (4). Indeed, studies have demonstrated that metals can influence the conformational stability of SOD1 and contribute to its propensity for misfolding (5). Moreover, post-mortem analyses of ALS patients have revealed alterations in copper and zinc levels in affected motor neurons, indicating a potential role in the disease process (6).

This narrative review aims to provide a comprehensive exploration of the intricate relationship between CuZnSOD and ALS. By integrating findings from both genetic and mechanistic studies, we seek to unravel the multifaceted connections between mutant SOD1, metal ions, oxidative stress, and motor neuron degeneration. Through a synthesis of key research studies and insights, we aspire to shed light on the underlying molecular mechanisms driving ALS pathogenesis, thus opening avenues for the development of novel therapeutic strategies. The convergence of expertise in neurobiology, metallochemistry, and cellular physiology in this review underscores the interdisciplinary nature of ALS research and the critical need for collaborative efforts in deciphering this devastating disease (7,8,9).

METHOD

For this narrative review, a comprehensive literature search was conducted to gather relevant research articles, reviews, and studies pertaining to the relationship between zinc superoxide dismutase (ZnSOD) and amyotrophic lateral sclerosis (ALS). Databases such as PubMed, Web of Science, and Google Scholar were systematically queried using combinations of keywords like "ZnSOD," "ALS," "oxidative stress," "pathogenesis," "treatment," and related terms.

The initial search yielded a substantial number of articles spanning various disciplines, including neurology, genetics, molecular biology, and pharmacology. Inclusion criteria encompassed articles published within the last two decades to ensure the inclusion of recent advancements, and a focus on peer-reviewed studies to ensure credibility. Studies elucidating the molecular mechanisms, genetic mutations, and therapeutic implications of ZnSOD in ALS were given priority.

The obtained articles were meticulously reviewed and categorized based on their relevance to the narrative review's scope. Through iterative analysis and discussion, key themes emerged, forming the backbone of the narrative structure. The findings from each identified theme were then synthesized to construct a cohesive narrative that portrays the intricate relationship between ZnSOD and ALS pathogenesis.

It's important to acknowledge that while this narrative review strives for accuracy and comprehensiveness, it does not follow a systematic review protocol. Instead, it seeks to provide an engaging and insightful exploration of the topic by weaving together various strands of research and expertise.

ALS Pathogenesis

Amyotrophic lateral sclerosis (ALS) represents a complex neurodegenerative disease that gradually erodes the intricate network connecting the brain and spinal cord to muscle fibers, inevitably leading to muscle weakness, paralysis, and, in the advanced stages, respiratory failure. This devastating disorder epitomizes a relentless progression, with symptoms emerging subtly, often as muscle twitching or stiffness, and then gradually intensifying to encompass more severe motor deficits, such as difficulty speaking, swallowing, and eventually breathing (4,5).

At its core, ALS owes its origins to a delicate balance of genetic predisposition and environmental factors. Among the myriad genetic mutations linked to ALS, the mutation in the SOD1 gene has garnered considerable attention. This particular mutation perturbs the function of the enzyme copper- zinc superoxide dismutase (ZnSOD or SOD1), ultimately contributing to the disease's progression (4).

Zinc Superoxide Dismutase (ZnSOD)

ZnSOD, a cornerstone in the defense against oxidative stress, takes on the vital role of neutralizing superoxide radicals within cells. This enzyme is finely attuned to the delicate balance of cellular redox equilibrium, effectively converting these reactive molecules into oxygen and hydrogen peroxide, lessening the potential damage they can inflict upon cellular structures. By doing so, ZnSOD becomes an essential guardian of cellular health, standing as a frontline defense mechanism against oxidative damage (3).

This enzyme's importance is most evident in neurons, which are particularly vulnerable to oxidative stress due to their high energy demands and rich lipid content. ZnSOD is thus instrumental in protecting neurons from oxidative insults that arise due to the body's normal metabolic activities, as well as those from external sources like pollution and inflammation (3,8).

Mutant SOD1 and Oxidative Stress

The discovery of mutant SOD1 proteins, primarily in familial ALS cases, added a complex layer to the disease's already intricate tapestry. These mutated forms of SOD1 exhibit an alarming tendency to aggregate and misfold, which compromises their natural function and introduces toxic properties. Instead of participating in neutralizing free radicals, mutant SOD1 catalyzes reactions that generate harmful oxidative molecules, amplifying cellular stress (6).

This toxic accumulation of misfolded SOD1 protein disrupts cellular machinery, leading to a cascade of events that heighten oxidative stress, initiate neuroinflammation, and culminate in motor neuron degeneration. Furthermore, mutant SOD1 aggregates instigate a domino effect, inducing neighboring proteins to also adopt aberrant conformations, thus perpetuating cellular dysfunction (6).

ZnSOD Dysfunction in ALS

Increasing evidence points to the significance of ZnSOD dysfunction in ALS pathogenesis. In the context of the disease, ZnSOD seems to lose its protective prowess. This dysregulation is evident in studies involving ALS patients and animal models, where decreased ZnSOD activity is correlated with increased oxidative stress. This heightened oxidative stress fosters a hostile environment for motor neurons, exacerbating their vulnerability (1,3,10).

The decline in ZnSOD activity contributes to a vicious cycle: as oxidative stress intensifies, motor neurons become more susceptible to damage, while compromised neurons further deteriorate ZnSOD's protective capacity. This intricate interplay ultimately culminates in the degeneration of motor neurons, the hallmark feature of ALS (1,10).

In unraveling the connection between ALS and ZnSOD, researchers are uncovering novel insights into the disease's origin and progression. This exploration serves as a foundation for potential therapeutic avenues, inspiring efforts to restore ZnSOD's function or counteract its dysregulation, with the aim of mitigating oxidative stress and preserving the vitality of motor neurons (1,3,10).

Challenges and Future Directions

As the intricate relationship between zinc superoxide dismutase (ZnSOD) and amyotrophic lateral sclerosis (ALS) becomes clearer, a multitude of challenges and promising avenues emerge in the pursuit of effective treatments. Transitioning ZnSOD-targeted therapies from the realm of research to the practical arena of clinical practice presents one of the foremost challenges. While research has highlighted the potential benefits of enhancing ZnSOD's function or addressing its dysregulation, translating these findings into tangible therapies demands careful consideration (9).

The road to clinical application is rife with hurdles, including the need to develop safe and efficient delivery methods for ZnSOD-based treatments. Finding approaches that ensure the targeted delivery of therapies to the central nervous system, where motor neurons are chiefly affected, is a complex task. Moreover, the intricate balance between increasing ZnSOD activity and avoiding potential adverse effects must be meticulously navigated to ensure therapeutic success without triggering unintended consequences (6).

One-size-fits-all interventions may not suffice in the diverse landscape of ALS, as the disease's genetic underpinnings vary among individuals. Thus, the imperative of personalized treatment strategies based on patients' unique genetic profiles becomes evident. Genetic variations influence disease progression, therapeutic responses, and even the manifestation of side effects. Tailoring interventions to individuals' genetic makeup could optimize treatment efficacy while minimizing potential risks, exemplifying the precision medicine paradigm (5,8).

Interdisciplinary collaboration stands as a cornerstone in advancing our understanding of ALS and exploiting the potential of ZnSOD-based therapies. The multifaceted nature of ALS necessitates the synergy of various fields, including neurology, genetics, molecular biology, pharmacology, and nanotechnology. Collaborative efforts can shed light on the intricate nuances of ZnSOD's role in ALS and help devise multifaceted strategies that tackle the disease from different angles. By fostering communication between experts across disciplines, innovative treatment approaches can be nurtured, bringing us closer to effective ALS interventions.

The path forward demands relentless dedication to ongoing research. The dynamic landscape of ALS and the intricacies of ZnSOD's involvement necessitate continual exploration and refinement of our understanding. As new discoveries surface, refining existing therapies and unveiling novel approaches will be essential to pave the way for improved outcomes. Through persistent research efforts, the intricate web connecting ZnSOD, oxidative stress, and ALS progression can be unraveled, propelling us closer to transformative therapeutic breakthroughs (5,8).

In conclusion, the challenges presented by the intricate relationship between ZnSOD and ALS are matched only by the promising possibilities they offer. Navigating these challenges, from translating research into clinical applications to personalizing treatments and fostering interdisciplinary collaboration, requires a concerted effort from researchers, clinicians, and policymakers. The interplay between ZnSOD and ALS continues to captivate researchers, reminding us of the complexity of the human body and the collective potential to alleviate the burden of neurodegenerative diseases.

CONCLUSION

In conclusion, this review stresses how vital zinc superoxide dismutase (ZnSOD) is in protecting motor neurons from oxidative stress in amyotrophic lateral sclerosis (ALS). There's real promise in focusing on ZnSOD for potential treatments to slow down or stop ALS progression. But, getting these treatments from the lab to patients is a big challenge, dealing with how to deliver them, the right doses, and tailoring treatments to each person based on their genes. Collaboration across different fields and continued research are key to understanding ALS better and moving closer to effective treatments. This gives hope for a future where ALS's impact can be lessened, bringing us closer to a world without its heavy burden.

Acknowledgements: None declared.

Conflict of Interest Statement: The authors declare that they have no conflict of interest.

REFERENCES

1. Ince PG, Shaw PJ, Slade JY, Jones C, Hudgson P. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol 1996;92(4):395-403. doi: 10.1007/s004010050535. PMID: 8891072.

2. Rakhit R, Chakrabartty A. Structure, folding, and misfolding of Cu,Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta 2006;1762(11-12):1025-1037. DOI: 10.1016/j.bbadis.2006.05.004. PMID: 16814528.

3. Furukawa Y, O'Halloran TV. Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. Antioxid Redox Signal. 2006;8(5-6):847-67. doi: 10.1089/ars.2006.8.847. PMID: 16771675; PMCID: PMC1633719.

4. Sannigrahi A, Chowdhury S, Das B, Banerjee A, Halder A, Kumar A, Saleem M, Naganathan AN, Karmakar S, Chattopadhyay K. The metal cofactor zinc and interacting membranes modulate SOD1 conformation-aggregation landscape in an in vitro ALS model. Elife 2021;10:e61453. doi: 10.7554/eLife.61453. PMID: 33825682; PMCID: PMC8087447.

5. Tokuda E, Takei YI, Ohara S, Fujiwara N, Hozumi I, Furukawa Y. Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis. Mol Neurodegener 2019;14(1):42. doi: 10.1186/s13024-019-0341-5. PMID: 31744522; PMCID: PMC6862823.

6. Furukawa Y, Tokuda E. Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis? Transl Neurodegener 2020;9(1):33. doi: 10.1186/ s40035-020-00209-y. PMID: 32811540; PMCID: PMC7437001.

7. Koski L, Ronnevi C, Berntsson E, Wärmländer SKTS, Roos PM. Metals in ALS TDP-43 Pathology. Int J Mol Sci 2021;22(22):12193. doi: 10.3390/ijms222212193. PMID: 34830074; PMCID: PMC8622279.

8. Tokuda E, Takei Yi, Ohara S et al. Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis. Mol Neurodegeneration 2019; 14, 42.